SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Presenting Pattern of Atrial Fibrillation and Outcomes of Early Rhythm Control Therapy.

Goette, A; Borof, K; Breithardt, G; Camm, AJ; Crijns, HJGM; Kuck, K-H; Wegscheider, K; Kirchhof, P; EAST-AFNET 4 Investigators (2022) Presenting Pattern of Atrial Fibrillation and Outcomes of Early Rhythm Control Therapy. J Am Coll Cardiol, 80 (4). pp. 283-295. ISSN 1558-3597 https://doi.org/10.1016/j.jacc.2022.04.058
SGUL Authors: Camm, Alan John

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (1MB) | Preview

Abstract

BACKGROUND: Whether atrial fibrillation (AF) pattern or timing of AF therapy modifies the effectiveness of early rhythm control (ERC) is not known. OBJECTIVES: This study sought to compare clinical characteristics and outcomes in patients presenting with different AF patterns on ERC vs usual care. METHODS: The effects of ERC were compared in first-diagnosed AF (FDAF), paroxysmal AF (paroxAF), and persistent AF (persAF) in this prespecified analysis of the EAST-AFNET 4 (Early treatment of atrial fibrillation for stroke prevention) trial. Associations between AF pattern and primary outcomes (first primary outcome: cardiovascular death, stroke, and hospitalization for heart failure and acute coronary syndrome; second primary outcome: nights spent in hospital per year) were compared over a mean follow-up of 5.1 years. Changes in health-related quality of life were assessed by the EQ-5D. RESULTS: FDAF patients (n = 1,048, enrolled 7 days after diagnosing AF) were slightly older (71 years of age, 48.0% female) than patients with paroxAF (n = 994, 70 years of age, 50.0% female) and persAF (n = 743, 70 years of age, 38.0% female). ERC reduced the primary outcome in all 3 AF patterns. Hospitalizations for acute coronary syndrome were highest in FDAF (incidence rate ratio [IRR]: 1.50; 95% CI: 0.83-2.69; P for interaction = 0.032) compared with paroxAF (IRR: 0.64; 95% CI: 0.32-1.25) and persAF (IRR: 0.50; 95% CI: 0.25-1.00). FDAF patients spent more nights in hospital (IRR: 1.38; 95% CI: 1.12-1.70; P for interaction = 0.004) than paroxAF (IRR: 0.84; 95% CI: 0.67-1.03), and persAF (IRR: 1.02; 95% CI: 0.80-1.30) patients. ERC improved health-related quality of life (EQ-5D score) in patients with paroxAF and persAF but not in patients with FDAF (P = 0.019). CONCLUSIONS: ERC reduces the first primary composite outcome in all AF patterns. Patients with FDAF are at high risk for hospitalization and acute coronary syndrome, particularly on ERC. (Early treatment of atrial fibrillation for stroke prevention trial; ISRCTN04708680; Early Treatment of Atrial Fibrillation for Stroke Prevention Trial [EAST]; NCT01288352; Early treatment of Atrial fibrillation for Stroke prevention Trial [EAST]; EudraCT2010-021258-20).

Item Type: Article
Additional Information: @ 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: acute coronary syndrome, atrial fibrillation, heart failure, hospitalization, outcome, stroke, therapy, Acute Coronary Syndrome, Adult, Atrial Fibrillation, Female, Humans, Male, Middle Aged, Quality of Life, Secondary Prevention, Stroke, EAST-AFNET 4 Investigators, Humans, Atrial Fibrillation, Quality of Life, Adult, Middle Aged, Female, Male, Stroke, Acute Coronary Syndrome, Secondary Prevention, Acute Coronary Syndrome, Adult, Atrial Fibrillation, Female, Humans, Male, Middle Aged, Quality of Life, Secondary Prevention, Stroke, acute coronary syndrome, atrial fibrillation, heart failure, hospitalization, outcome, stroke, therapy, 1102 Cardiorespiratory Medicine and Haematology, 1117 Public Health and Health Services, Cardiovascular System & Hematology
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Journal or Publication Title: J Am Coll Cardiol
ISSN: 1558-3597
Language: eng
Dates:
DateEvent
26 July 2022Published
18 July 2022Published Online
18 April 2022Accepted
Publisher License: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0
Projects:
Project IDFunderFunder ID
965286Horizon 2020UNSPECIFIED
EU IMI 116074BigData@HeartUNSPECIFIED
847770AFFECT-AFUNSPECIFIED
965286MAESTRIAUNSPECIFIED
PG/17/30/32961British Heart Foundationhttp://dx.doi.org/10.13039/501100000274
PG/20/22/35093British Heart Foundationhttp://dx.doi.org/10.13039/501100000274
AA/18/2/34218British Heart Foundationhttp://dx.doi.org/10.13039/501100000274
PubMed ID: 35863844
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/114621
Publisher's version: https://doi.org/10.1016/j.jacc.2022.04.058

Actions (login required)

Edit Item Edit Item